The “miracle drug”, aka GLP-1 or Ozempic, swept the world with a solution for weight loss and to fight diabetes. But now, after all that hype, the patents are about to expire, and the prices are too high. Are healthcare investors fearing that profits might be dropping to zero? And with elections right around the corner, what are the candidates saying about imposing price gaps?